Use of anti-FAM19A5 antibodies for treating cancers
US11560425B2 · kind B2 · utility
5Cited by
42References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 27, 2018 |
| Grant date | Jan 24, 2023 |
| Priority date | — |
| Expiry date | Jan 25, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/565
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to promote a blood vessel normalization and treat a disease (e.g., cancer) in a subject in need thereof, e.g., by promoting a blood vessel normalization.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.